Format

Send to

Choose Destination
Minerva Cardioangiol. 2013 Jun;61(3):323-31.

Mesoglycan treatment in Raynaud phenomenon: a case series.

Author information

1
Ambulatory of Vascular Diagnostic, Geriatric Medicine Villa Verde, Taranto, Italy. a.dibiase@email.it

Abstract

AIM AND METHODS:

Raynaud's phenomenon (RP) is a common clinical disorder without cure or gold standard therapy. Mesoglycan is an well-balanced extract of glycosaminoglycans active on endothelial layers at microcirculatory level. Herein we investigated for the first time the efficacy and tolerability of mesoglycan on vasospastic attacks and videocapillaroscopy patterns in 25 consecutive patients with primary or secondary RP.

RESULTS AND CONCLUSION:

During 12 months of add-on therapy, mesoglycan obtained a remarkable and significant reduction in the frequency of Raynaud attacks and an improvement of the capillaroscopy abnormalities in most patients, without important adverse effects, revealing a good convenience in the management if this condition.

PMID:
23681135
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Minerva Medica
Loading ...
Support Center